India high court bans promotion of Roche’s Herceptin biosimilars by Biocon, Mylan
HONG KONG – The High Court of Delhi has forbidden Biocon Ltd. and Mylan Inc. from comparing Canmab and Hertraz to Roche AG’s breast cancer drug Herceptin (trastuzumab), even though they were approved as biosimilar versions of the drug.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter